PharmaCyte Biotech Inc
For the period ended Jan 31, 2024. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jan 31, 2024 · Filed Mar 18, 2024
PMCB$0.41+13.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit No. | Description | Location |
| 4.1 | Form of Series A Warrant. | Incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed on November 16, 2023 |
| 4.2 | Form of Series B Warrant. | Incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed on November 16, 2023 |
| 10.1 | Purchase Agreement, dated November 14, 2023, by and between the Company and Femasys Inc. | Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on November 16, 2023 |
| 10.2 | Registration Rights Agreement, dated November 14, 2023, by and between the Company and Femasys Inc. | Incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K filed on November 16, 2023 |
| 10.3 | Collaboration Agreement, dated November 14, 2023, by and between the Company and Femasys Inc. | Incorporated by reference to Exhibit 10.4 of the Company’s Current Report on Form 8-K filed on November 16, 2023 |
| 10.4 | Form of Senior Unsecured Convertible Note. | Incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed on November 16, 2023 |
| 31.1 | Principal Executive Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith |
| 31.2 | Principal Financial Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith |
| 32.1 | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002 | Furnished herewith |
| 32.2 | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002 | Furnished herewith |
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and included in exhibit 101). |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.